Therapeutic approaches that promote ferroptosis in tumor cells and immunosuppressive cells (such as M2‐type macrophages, Treg cells, and MDSCs), as well as reducing CD8+ T cell ferroptosis, are effective therapeutic strategies that can decrease the occurrence of resistance to immune checkpoint inhibitors. The gene discussed is CD8A; the disease is neoplasm.